The Value of Left Ventricular Support in Patients With Reduced Left Ventricular Function Undergoing Extensive Revascularization: An Analysis From the PROTECT-II Randomized Trial

David A. Burke; Harun Kundi; Alexandra Almonacid; William O'Neill; Jeffrey Moses; Neal Kleiman; Simon Dixon; Igor Palacios; Luis A. Guzman; E. Magnus Ohman; Jeffrey J. Popma; Duane S. Pinto

doi:10.1016/j.jcin.2019.07.050

The Value of Left Ventricular Support in Patients With Reduced Left Ventricular Function Undergoing Extensive Revascularization: An Analysis From the PROTECT-II Randomized Trial

David A. Burke, Harun Kundi, Alexandra Almonacid, William O'Neill, Jeffrey Moses, Neal Kleiman, Simon Dixon, Igor Palacios, Luis A. Guzman, E. Magnus Ohman, Jeffrey J. Popma, Duane S. Pinto

Research output: Contribution to journal › Letter › peer-review

10 Scopus citations

Original language	English (US)
Pages (from-to)	1985-1987
Number of pages	3
Journal	JACC: Cardiovascular Interventions
Volume	12
Issue number	19
DOIs	https://doi.org/10.1016/j.jcin.2019.07.050
State	Published - Oct 14 2019

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jcin.2019.07.050

Cite this

Burke, D. A., Kundi, H., Almonacid, A., O'Neill, W., Moses, J., Kleiman, N., Dixon, S., Palacios, I., Guzman, L. A., Ohman, E. M., Popma, J. J., & Pinto, D. S. (2019). The Value of Left Ventricular Support in Patients With Reduced Left Ventricular Function Undergoing Extensive Revascularization: An Analysis From the PROTECT-II Randomized Trial. JACC: Cardiovascular Interventions, 12(19), 1985-1987. https://doi.org/10.1016/j.jcin.2019.07.050

The Value of Left Ventricular Support in Patients With Reduced Left Ventricular Function Undergoing Extensive Revascularization: An Analysis From the PROTECT-II Randomized Trial. / Burke, David A.; Kundi, Harun; Almonacid, Alexandra et al.
In: JACC: Cardiovascular Interventions, Vol. 12, No. 19, 14.10.2019, p. 1985-1987.

Research output: Contribution to journal › Letter › peer-review

Burke, DA, Kundi, H, Almonacid, A, O'Neill, W, Moses, J, Kleiman, N, Dixon, S, Palacios, I, Guzman, LA, Ohman, EM, Popma, JJ & Pinto, DS 2019, 'The Value of Left Ventricular Support in Patients With Reduced Left Ventricular Function Undergoing Extensive Revascularization: An Analysis From the PROTECT-II Randomized Trial', JACC: Cardiovascular Interventions, vol. 12, no. 19, pp. 1985-1987. https://doi.org/10.1016/j.jcin.2019.07.050

@article{e6a22b2ac1254160bcc08241d8447b69,

title = "The Value of Left Ventricular Support in Patients With Reduced Left Ventricular Function Undergoing Extensive Revascularization: An Analysis From the PROTECT-II Randomized Trial",

author = "Burke, {David A.} and Harun Kundi and Alexandra Almonacid and William O'Neill and Jeffrey Moses and Neal Kleiman and Simon Dixon and Igor Palacios and Guzman, {Luis A.} and Ohman, {E. Magnus} and Popma, {Jeffrey J.} and Pinto, {Duane S.}",

note = "Funding Information: Please note: Dr. O'Neill has been a consultant for Abiomed, Edwards Lifesciences, Boston Scientific, and Abbott. Dr. Ohman has been a consultant for 3D Communications, Abiomed, ACI Clinical, Biotie, Cara Therapeutics, Cardinal Health, Faculty Connection, Imbria, Impulse Medical, Janssen Pharmaceuticals, Medscape, Milestone Pharmaceuticals, and Xylocor; and has received research grants from Abiomed, Chiesi, and Portola. Dr. Popma has served on a medical advisory board for Boston Scientific; and has received institutional grants from Boston Scientific; Medtronic, Abiomed, and Abbott. Dr. Pinto is a consultant for Abbott Vascular, Abiomed, Teleflex, NuPulse, Medtronic, and Opsens; has received institutional grants from Boston Scientific, and received stock options from NuPulse. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: Please note: Dr. O'Neill has been a consultant for Abiomed, Edwards Lifesciences, Boston Scientific, and Abbott. Dr. Ohman has been a consultant for 3D Communications, Abiomed, ACI Clinical, Biotie, Cara Therapeutics, Cardinal Health, Faculty Connection, Imbria, Impulse Medical, Janssen Pharmaceuticals, Medscape, Milestone Pharmaceuticals, and Xylocor; and has received research grants from Abiomed, Chiesi, and Portola. Dr. Popma has served on a medical advisory board for Boston Scientific; and has received institutional grants from Boston Scientific; Medtronic, Abiomed, and Abbott. Dr. Pinto is a consultant for Abbott Vascular, Abiomed, Teleflex, NuPulse, Medtronic, and Opsens; has received institutional grants from Boston Scientific, and received stock options from NuPulse. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.",

year = "2019",

month = oct,

day = "14",

doi = "10.1016/j.jcin.2019.07.050",

language = "English (US)",

volume = "12",

pages = "1985--1987",

journal = "JACC: Cardiovascular Interventions",

issn = "1936-8798",

publisher = "Elsevier",

number = "19",

}

TY - JOUR

T1 - The Value of Left Ventricular Support in Patients With Reduced Left Ventricular Function Undergoing Extensive Revascularization

T2 - An Analysis From the PROTECT-II Randomized Trial

AU - Burke, David A.

AU - Kundi, Harun

AU - Almonacid, Alexandra

AU - O'Neill, William

AU - Moses, Jeffrey

AU - Kleiman, Neal

AU - Dixon, Simon

AU - Palacios, Igor

AU - Guzman, Luis A.

AU - Ohman, E. Magnus

AU - Popma, Jeffrey J.

AU - Pinto, Duane S.

N1 - Funding Information: Please note: Dr. O'Neill has been a consultant for Abiomed, Edwards Lifesciences, Boston Scientific, and Abbott. Dr. Ohman has been a consultant for 3D Communications, Abiomed, ACI Clinical, Biotie, Cara Therapeutics, Cardinal Health, Faculty Connection, Imbria, Impulse Medical, Janssen Pharmaceuticals, Medscape, Milestone Pharmaceuticals, and Xylocor; and has received research grants from Abiomed, Chiesi, and Portola. Dr. Popma has served on a medical advisory board for Boston Scientific; and has received institutional grants from Boston Scientific; Medtronic, Abiomed, and Abbott. Dr. Pinto is a consultant for Abbott Vascular, Abiomed, Teleflex, NuPulse, Medtronic, and Opsens; has received institutional grants from Boston Scientific, and received stock options from NuPulse. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: Please note: Dr. O'Neill has been a consultant for Abiomed, Edwards Lifesciences, Boston Scientific, and Abbott. Dr. Ohman has been a consultant for 3D Communications, Abiomed, ACI Clinical, Biotie, Cara Therapeutics, Cardinal Health, Faculty Connection, Imbria, Impulse Medical, Janssen Pharmaceuticals, Medscape, Milestone Pharmaceuticals, and Xylocor; and has received research grants from Abiomed, Chiesi, and Portola. Dr. Popma has served on a medical advisory board for Boston Scientific; and has received institutional grants from Boston Scientific; Medtronic, Abiomed, and Abbott. Dr. Pinto is a consultant for Abbott Vascular, Abiomed, Teleflex, NuPulse, Medtronic, and Opsens; has received institutional grants from Boston Scientific, and received stock options from NuPulse. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2019/10/14

Y1 - 2019/10/14

UR - http://www.scopus.com/inward/record.url?scp=85072606114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072606114&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2019.07.050

DO - 10.1016/j.jcin.2019.07.050

M3 - Letter

C2 - 31601396

AN - SCOPUS:85072606114

SN - 1936-8798

VL - 12

SP - 1985

EP - 1987

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

IS - 19

ER -

The Value of Left Ventricular Support in Patients With Reduced Left Ventricular Function Undergoing Extensive Revascularization: An Analysis From the PROTECT-II Randomized Trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this